News
Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...
Novo Nordisk (NYSE: NVO) is quite the divisive stock among both investors and analysts these days. Although its high-profile ...
Zacks Investment Research on MSN18h
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a “Hold” rating on ...
The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...
C’était l’histoire dont tout le monde parlait. En 2024, Novo Nordisk, grâce à ses traitements révolutionnaires contre l’obésité, s’imposait comme la première capitalisation boursière d’Europe, ...
Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...
The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback